发布求助
文献互助 智能选刊 最新文献

Women’s Health Investigation最新文献

筛选
英文 中文
Application of the CARE guideline as reporting standard in the Women’s Health Investigation 在妇女健康调查中应用CARE指南作为报告标准
Women’s Health Investigation Pub Date : 2019-12-01 DOI: 10.21037/whi.2019.10.01
{"title":"Application of the CARE guideline as reporting standard in the Women’s Health Investigation","authors":"","doi":"10.21037/whi.2019.10.01","DOIUrl":"https://doi.org/10.21037/whi.2019.10.01","url":null,"abstract":"","PeriodicalId":125517,"journal":{"name":"Women’s Health Investigation","volume":"1 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2019-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"114751486","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Immune checkpoint inhibitors: a potential treatment breakthrough for metastatic triple-negative breast cancer? 免疫检查点抑制剂:转移性三阴性乳腺癌的潜在治疗突破?
Women’s Health Investigation Pub Date : 2019-08-04 DOI: 10.21037/WHI.2019.03.01
E. Pons-Tostivint, J. Delord, F. Dalenc
{"title":"Immune checkpoint inhibitors: a potential treatment breakthrough for metastatic triple-negative breast cancer?","authors":"E. Pons-Tostivint, J. Delord, F. Dalenc","doi":"10.21037/WHI.2019.03.01","DOIUrl":"https://doi.org/10.21037/WHI.2019.03.01","url":null,"abstract":"A milestone in oncology has been reached in recent years with the advent of immune checkpoint inhibitors (ICIs) which target programmed cell death protein 1 (PD-1) or its ligand, PD-L1, and cytotoxic T-lymphocyte-associated protein 4 (CTLA4). ICIs were first approved by the Food and Drug Administration (FDA) for melanoma in 2011 and subsequently in several other tumor types. In contrast to more immunogenic solid tumor types, breast cancer (BC) is typically not characterized by a high tumor mutation burden which is known as one of the predictive biomarkers of response to ICI (well described in melanoma and lung cancer), and so it has been considered potentially less immunogenic.","PeriodicalId":125517,"journal":{"name":"Women’s Health Investigation","volume":"1605 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2019-08-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"127449340","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Gestational weight gain and pregnancy outcomes: where does delivery timing fit in? 妊娠期体重增加与妊娠结局:分娩时间在哪里?
Women’s Health Investigation Pub Date : 2019-01-01 DOI: 10.21037/WHI.2019.01.01
Joseph S. Fixler, E. Defranco
{"title":"Gestational weight gain and pregnancy outcomes: where does delivery timing fit in?","authors":"Joseph S. Fixler, E. Defranco","doi":"10.21037/WHI.2019.01.01","DOIUrl":"https://doi.org/10.21037/WHI.2019.01.01","url":null,"abstract":"Gestational weight gain is a modifiable risk factor that impacts both short and long term maternal and child health (1). In 2009, the Institute of Medicine (IOM, now the National Academy of Medicine) published guidelines, “Weight Gain in Pregnancy, Reexamining the Guidelines”, recommending pregnancy weight gain goals stratified based on prepregnancy BMI (2). Achieving these goals in the United States has been difficult: in 2012–2013, only 32.1% of parturients met the recommended gestational weight gain target (3). Nonetheless, there is evidence supporting the use of dietary and lifestyle modifications to improve both maternal weight gain and obstetric outcomes (4,5).","PeriodicalId":125517,"journal":{"name":"Women’s Health Investigation","volume":"1 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2019-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"129785473","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 2
Immunotherapy in cervical cancer: historic breakthroughs beating checkpoints 宫颈癌免疫治疗:历史性突破击败检查点
Women’s Health Investigation Pub Date : 2018-11-01 DOI: 10.21037/whi.2018.11.01
R. Penson
{"title":"Immunotherapy in cervical cancer: historic breakthroughs beating checkpoints","authors":"R. Penson","doi":"10.21037/whi.2018.11.01","DOIUrl":"https://doi.org/10.21037/whi.2018.11.01","url":null,"abstract":"Who benefits from immunotherapy? What constitutes a breakthrough? Where do the blockbuster pharmaceutical come from? When are clinical and scientific dreams realized? Why does getting a drug to market require such a huge, long and costly investment? How do we pick the winners?","PeriodicalId":125517,"journal":{"name":"Women’s Health Investigation","volume":"40 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2018-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"124705163","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整，为了账户安全，请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
请完成安全验证×
相关产品
×
本文献相关产品
联系我们：info@booksci.cn Book学术提供免费学术资源搜索服务，方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号：481959085
Book学术官方微信